Provided herein are compositions for treating a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage in a subject, pharmaceutical compositions comprising the compositions and pharmaceutically acceptable excipients, and pharmaceutical formulations comprising the compositions. Provided also herein are methods of treating a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage in a subject, and methods of regulating inflammation, antioxidant enzymes, and apoptosis in a subject having a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage.

Provided herein are compositions for treating a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage in a subject, pharmaceutical compositions comprising the compositions and pharmaceutically acceptable excipients, and pharmaceutical formulations comprising the compositions. Provided also herein are methods of treating a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage in a subject, and methods of regulating inflammation, antioxidant enzymes, and apoptosis in a subject having a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage.

Provided herein are compositions for treating a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage in a subject, pharmaceutical compositions comprising the compositions and pharmaceutically acceptable excipients, and pharmaceutical formulations comprising the compositions. Provided also herein are methods of treating a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage in a subject, and methods of regulating inflammation, antioxidant enzymes, and apoptosis in a subject having a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage.

A topical TCM composition and topical preparation for a cervical disease, and preparation methods thereof are provided. The topical TCM composition is prepared from the following components in parts by weight: Cortex Ailanthi; fried Ginkgo nut; Phellodendron amurense; Cnidium monnieri fruit; Radix Sophorae Flavescentis; Sichuan pepper; Cyrtomium fortunei; Indigo naturalis; Ligustrum lucidum; Halloysitum Rubrum; Radix rehmanniae praeparata; Houttuynia Cordata; charred Zingiberis Rhizoma Recens; Radix Boehmeriae; Rhizoma Atractylodis; Chinese smartweed; Herba Patriniae; Radix et Rhizoma Rhei; Solanum nigrum; Rhizoma Bletillae; Radix Notoginseng; Fructus Piperis Longi; and licorice root.

A topical TCM composition and topical preparation for a cervical disease, and preparation methods thereof are provided. The topical TCM composition is prepared from the following components in parts by weight: Cortex Ailanthi; fried Ginkgo nut; Phellodendron amurense; Cnidium monnieri fruit; Radix Sophorae Flavescentis; Sichuan pepper; Cyrtomium fortunei; Indigo naturalis; Ligustrum lucidum; Halloysitum Rubrum; Radix rehmanniae praeparata; Houttuynia Cordata; charred Zingiberis Rhizoma Recens; Radix Boehmeriae; Rhizoma Atractylodis; Chinese smartweed; Herba Patriniae; Radix et Rhizoma Rhei; Solanum nigrum; Rhizoma Bletillae; Radix Notoginseng; Fructus Piperis Longi; and licorice root.

A pharmaceutic composition for treating an allergic skin disorder. It has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by weight of the active component, which accounts for 5-35% by weight of the overall pharmaceutic composition.

A pharmaceutic composition for treating an allergic skin disorder. It has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by weight of the active component, which accounts for 5-35% by weight of the overall pharmaceutic composition.

Disclosed herein is a method for manufacturing a composition promoting recovery from a bone fracture, the method including preparing a mixture of Angelica gigas, Cnidium officinale, Phlomis umbrosa, Astragalus membranceus, Amomi fructus, Citri unshius pericarpium, Drynariae Rhizoma, Codonopsis Pilosulae Radix, frankincense, and myrrh, aging the mixture, smoking the mixture, drying the mixture and grinding the dried mixture into a powder, and extracting a liquid from the powder.

Disclosed herein is a method for manufacturing a composition promoting recovery from a bone fracture, the method including preparing a mixture of Angelica gigas, Cnidium officinale, Phlomis umbrosa, Astragalus membranceus, Amomi fructus, Citri unshius pericarpium, Drynariae Rhizoma, Codonopsis Pilosulae Radix, frankincense, and myrrh, aging the mixture, smoking the mixture, drying the mixture and grinding the dried mixture into a powder, and extracting a liquid from the powder.

Disclosed herein is a method for manufacturing a composition promoting bone density enhancement, the method including preparing a mixture of Angelica gigas, Cnidium officinale, Phlomis umbrosa, Astragalus membranceus, Amomi fructus, Citri unshius pericarpium, Drynariae rhizoma, Codonopsis pilosulae radix, frankincense, and myrrh, aging the mixture, drying the mixture and grinding the dried mixture into a powder, and extracting a liquid from the powder.